...previously used a mitochondrial priming assay to stratify cancer patients into chemotherapy responders and non-responders. Eutropics Pharmaceuticals Inc....
...Eutropics granted Tolero exclusive rights to use Eutropics’ Praedicare-Dx biomarker platform in the development of Tolero’s... ...germ cell tumors. The partners did not respond to inquiries (see BioCentury, Jan. 20, 2014). Eutropics Pharmaceuticals Inc....
...Jan. 20). Eutropics Pharmaceuticals Inc. , Cambridge, Mass. National Institutes of Health , Bethesda, Md. Business: Pharmacogenetics Eutropics... ...Praedicare-Dx biomarker technology for personalized medicine approaches for managing patients with acute myelogenous leukemia (AML). Eutropics...
...The companies partnered to use Eutropics' Praedicare-Dx biomarker platform to predict responses to Tolero's compounds to... ...to carry out clinical correlation studies of alvocidib in combination with cytarabine in AML patients. Eutropics... ...negotiation rights with respect to manufacturing the product for Tolero and becoming a commercialization partner. Eutropics Pharmaceuticals Inc....
...predicts patient response to chemotherapy by directly measuring how prone cells are to apoptosis. 1 Eutropics Pharmaceuticals Inc.... ...Results were published in Science . Clinical utility Letai has exclusively licensed the assay to Eutropics... ...member called myeloid cell leukemia sequence 1 (MCL1). Michael Cardone, cofounder, president and CEO of Eutropics...
...in combination therapies," said Anthony Letai, cofounder and chairman of the scientific advisory board for Eutropics Pharmaceuticals Inc.... ...BCL2, BCL-X L and BCL2-like 2 ( BCL2L2 ; BCLW ). Zeroing in on MCL1 Eutropics... ...Boston, Mass. Brigham and Women's Hospital , Boston, Mass. Dana-Farber Cancer Institute , Boston, Mass. Eutropics Pharmaceuticals Inc....
...Mcl-1- and BCL2-dependent cancers; profiling technology licensed to Eutropics Pharmaceuticals Inc.; profiling technology available for licensing from Eutropics...
...previously used a mitochondrial priming assay to stratify cancer patients into chemotherapy responders and non-responders. Eutropics Pharmaceuticals Inc....
...Eutropics granted Tolero exclusive rights to use Eutropics’ Praedicare-Dx biomarker platform in the development of Tolero’s... ...germ cell tumors. The partners did not respond to inquiries (see BioCentury, Jan. 20, 2014). Eutropics Pharmaceuticals Inc....
...Jan. 20). Eutropics Pharmaceuticals Inc. , Cambridge, Mass. National Institutes of Health , Bethesda, Md. Business: Pharmacogenetics Eutropics... ...Praedicare-Dx biomarker technology for personalized medicine approaches for managing patients with acute myelogenous leukemia (AML). Eutropics...
...The companies partnered to use Eutropics' Praedicare-Dx biomarker platform to predict responses to Tolero's compounds to... ...to carry out clinical correlation studies of alvocidib in combination with cytarabine in AML patients. Eutropics... ...negotiation rights with respect to manufacturing the product for Tolero and becoming a commercialization partner. Eutropics Pharmaceuticals Inc....
...predicts patient response to chemotherapy by directly measuring how prone cells are to apoptosis. 1 Eutropics Pharmaceuticals Inc.... ...Results were published in Science . Clinical utility Letai has exclusively licensed the assay to Eutropics... ...member called myeloid cell leukemia sequence 1 (MCL1). Michael Cardone, cofounder, president and CEO of Eutropics...
...in combination therapies," said Anthony Letai, cofounder and chairman of the scientific advisory board for Eutropics Pharmaceuticals Inc.... ...BCL2, BCL-X L and BCL2-like 2 ( BCL2L2 ; BCLW ). Zeroing in on MCL1 Eutropics... ...Boston, Mass. Brigham and Women's Hospital , Boston, Mass. Dana-Farber Cancer Institute , Boston, Mass. Eutropics Pharmaceuticals Inc....
...Mcl-1- and BCL2-dependent cancers; profiling technology licensed to Eutropics Pharmaceuticals Inc.; profiling technology available for licensing from Eutropics...